Emerson Electric Co. (EMR)  shares soared 5.2% in the last trading session to close at $142.85. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.1% loss over the past four weeks.Emerson’s rally is primarily driven by optimism over strong momentum in Intelligent Devices segment. Within the segment, EMR is seeing strength in the Final Control business, driven by solid momentum in power end markets. Also, robust growth across the A ...

Bristol Gate Capital Partners, an investment management company, published its Q3 2025 investor letter for the “US Equity Strategy”. A copy of the letter can be downloaded here. The strategy underperformed the benchmark, the S&P 500® Total Return Index, this quarter, but still surpassed the index in dividend growth. The underperformance was due to a lack of significant exposure to the AI/TMT sector or the Value sector, which provides advantages stemming from the Federal Reserve's rate cut. The portfolio ret ...

Thermo Fisher Scientific Inc. (NYSE:TMO) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View On December 15, Bank of America raised its price target on Thermo Fisher Scientific Inc. (NYSE:TMO) to $700 from $650 and kept a Buy rating on the shares. The firm said it was updating price targets across its Life Sciences & Diagnostic Tools coverage. According to the analyst, current headwinds are expected to ease, wit ...

Core Viewpoint - Thermo Fisher Scientific Inc. (TMO) is recognized as one of the best stocks to buy in the S&P 500, with a consensus Strong Buy rating from analysts and a one-year price target indicating a potential upside of 12% [1]. Analyst Updates - Wells Fargo raised its price target for TMO to $675 from $635, citing improved clarity on U.S. pharmaceutical policies and positive growth projections [2]. - Citigroup upgraded TMO's rating to Buy from Neutral and increased its price target to $660 from $580, driven by favorable trends in onshoring and pharmaceutical spending [3]. Company Overview - Thermo Fisher Scientific is a leading provider of life sciences solutions, laboratory products, diagnostics, analytical instruments, and biopharma services, with an 8% gain year-to-date in 2025 [4].

This article looks at the 14 Best S&P 500 Stocks to Buy Now.The broad market index fell 1.16% on Wednesday to close at 6,721.43. The dip marked the fourth successive day of decline, amid the ongoing AI infrastructure selloff.The downturn has been sparked by reports of a prominent Oracle investor exiting from one of its data center projects. Investors have also been displeased with Broadcom’s recent quarterly earnings, in which management cited AI sales squeezing margins.Brian Mulberry, client portfolio mana ...

Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter.  A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI World Index. YTD, the strategy rose 10.61% (net) compared to 18.86% and 17.83% for the indexes. The firm highlighted in the letter that the last six months represented one of the str ...

Core Insights - Thermo Fisher Scientific Inc. (TMO) is a leading provider of life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products, with a market cap of $220.3 billion [1] Performance Overview - TMO shares have underperformed compared to the broader market, gaining 8.7% over the past year, while the S&P 500 Index has increased by nearly 14.5% [2] - In 2025, TMO stock is up 13%, compared to the S&P 500's 16.5% rise year-to-date [2] Sector Comparison - TMO has outperformed the Health Care Select Sector SPDR Fund (XLV), which gained about 3.8% over the past year, and TMO's year-to-date gains surpass the ETF's 11.1% returns [3] Market Challenges - TMO's underperformance is attributed to economic weakness in China, pricing pressures, and cautious spending by academic institutions and governments [4] - Diagnostics in China are struggling, while Europe shows modest improvement, and the U.S. market remains stable but uncertain [4] Financial Performance - On October 22, TMO reported Q3 results, with an adjusted EPS of $5.79, exceeding Wall Street expectations of $5.50, and revenue of $11.1 billion, beating forecasts of $10.9 billion [5] - For the current fiscal year ending in December, analysts expect TMO's EPS to grow by 4% to $22.74 on a diluted basis [5] - TMO has a strong earnings surprise history, beating consensus estimates in each of the last four quarters [5] Analyst Ratings - Among 23 analysts covering TMO, the consensus rating is a "Strong Buy," with 16 "Strong Buy" ratings, two "Moderate Buys," and five "Holds" [6] - This rating configuration is less bullish than a month ago, when 17 analysts suggested a "Strong Buy" [7]

Core Insights - Diamond Hill Capital's "Large Cap Fund" underperformed the Russell 1000 Value Index in Q3 2025 despite a market rally, with the Russell 3000 Index gaining 8% and calendar-year returns exceeding 14% [1] Company Highlights - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted in the investor letter, showing a one-month return of 6.16% and a 52-week gain of 2.11%, with a closing stock price of $567.64 and a market capitalization of $213.267 billion as of November 5, 2025 [2] - The company reported a revenue growth of 3% in Q2, reaching $10.85 billion, and is ranked 26th among the 30 Most Popular Stocks Among Hedge Funds, with 117 hedge fund portfolios holding its stock at the end of Q2 2025 [4] - Diamond Hill Capital initiated four new positions in Q3 2025, including Thermo Fisher Scientific Inc., indicating a belief that its stock price does not reflect its long-term growth potential [3]

Core Insights - Emerson Electric reported quarterly earnings of $1.62 per share, matching the Zacks Consensus Estimate, and showing an increase from $1.48 per share a year ago [1] - The company posted revenues of $4.86 billion for the quarter ended September 2025, which was 0.6% below the Zacks Consensus Estimate, but up from $4.62 billion year-over-year [2] - Emerson Electric has surpassed consensus EPS estimates three times over the last four quarters, while it has only topped revenue estimates once in the same period [2] Earnings Performance - The earnings surprise for the previous quarter was +0.66%, with actual earnings of $1.52 per share compared to an expected $1.51 [1] - The current consensus EPS estimate for the upcoming quarter is $1.48, with expected revenues of $4.39 billion, and for the current fiscal year, the EPS estimate is $6.51 on revenues of $18.92 billion [7] Stock Performance and Outlook - Emerson Electric shares have increased by approximately 11.1% since the beginning of the year, while the S&P 500 has gained 15.1% [3] - The company's Zacks Rank is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Manufacturing - Electronics industry, to which Emerson Electric belongs, is currently ranked in the top 17% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8]

Core Viewpoint - Baron Health Care Fund's performance in Q3 2025 was a 5.39% increase, slightly outperforming the Russell 3000 Health Care Index's 5.05% gain, but lagging behind the broader Russell 3000 Index's 8.18% increase, primarily due to stock selection offset by negative impacts from sub-industry allocations and cash holdings during a rising market [1] Group 1: Fund Performance - The Baron Health Care Fund rose 5.39% in Q3 2025 compared to a 5.05% gain for its benchmark [1] - The fund's performance was similar to the benchmark, with solid stock selection being offset by negative effects from active sub-industry allocations and cash holdings [1] Group 2: Thermo Fisher Scientific Inc. (NYSE:TMO) - Thermo Fisher Scientific Inc. is highlighted as a key stock in the fund's portfolio, with a one-month return of 4.31% and a 52-week gain of 2.15% [2] - As of October 31, 2025, Thermo Fisher's stock closed at $567.39, with a market capitalization of $214.253 billion [2] - The fund added to its position in Thermo Fisher, which is expected to achieve 3% to 6% organic revenue growth in 2026 and 2027, with potential for mid-to-high single-digit adjusted operating income growth [3] - Management anticipates that beyond 2027, Thermo Fisher could deliver over 7% organic revenue growth due to positive long-term drivers in the life sciences tools industry [3] - Thermo Fisher Scientific's revenue grew 3% to $10.85 billion in Q2 2025, and it ranks 26th among the 30 most popular stocks among hedge funds, with 117 hedge fund portfolios holding its shares [4]